Welcome to our dedicated page for Chemomab Therapeutics Ltd. SEC filings (Ticker: CMMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chemomab Therapeutics Ltd. filings document a foreign private issuer focused on clinical-stage biotechnology and traded through American Depositary Shares. Its Form 6-K reports furnish operating updates, quarterly and year-end financial results, unaudited consolidated financial statements, management discussion and analysis, and press releases on the nebokitug program in primary sclerosing cholangitis.
The filing record also covers ADS and capital-structure matters, including at-the-market offering arrangements, ADS ratio-adjustment disclosures, shelf registration and equity incentive registration references, and annual general meeting materials. Proxy-related filings describe shareholder voting procedures for ADS holders, director elections, compensation policy approval, authorized share capital amendments, auditor re-appointment, quorum matters, and governance under Israeli company law.
Chemomab Therapeutics Ltd. (CMMB) received an amended Schedule 13D from HBM Healthcare Investments (Cayman) Ltd., which reports beneficial ownership of 80,971,680 Ordinary Shares, representing 12.5% of Chemomab’s outstanding ordinary shares, with sole voting and dispositive power over this stake.
The filing explains that HBM holds American Depositary Shares, with each ADS representing 80 Ordinary Shares, and therefore reports ownership in terms of Ordinary Shares. On September 7, 2026, HBM notified Chemomab that it elected to exercise its Pre-Funded Warrants in order to carry out its voting obligations under an existing Shareholder Support Agreement.
Chemomab Therapeutics Ltd. (CMMB) director Neil Harris Cohen reported both share sales and option awards. He sold 1,000 American Depositary Shares at $2.80 on August 28, 2026 and 1,304 ADS at $2.85 on August 27, 2026. Cohen also reported multiple prior grants of stock options to purchase ADS, many of which are noted as fully vested and exercisable as of this report.
Chemomab Therapeutics Ltd. (CMMB) reported unaudited results for the six months ended June 30, 2026, with a net loss of $3.94 million versus $5.38 million a year earlier. Research and development expenses fell to $2.07 million (from $3.78 million), while general and administrative expenses were $2.02 million. Cash, cash equivalents and short-term deposits totaled $6.7 million, and net cash used in operating activities was $3.74 million, prompting management to state that these factors raise substantial doubt about the company’s ability to continue as a going concern without new funding.
Chemomab disclosed a definitive merger agreement with Scipher Medicine, involving a U.S. domestication and combination under Snowdrift Parent Corporation, with Scipher investors committing to a Concurrent PIPE Investment of at least $30 million as a closing condition. After the merger and before the PIPE, former Scipher securityholders are expected to own about 68% and Chemomab holders about 32% of the combined company on a fully diluted basis. Existing Chemomab ADS and vested option holders will receive contingent value rights (CVRs) tied to milestones for nebokitug. The combined company plans a Phase 2 precision-medicine trial of nebokitug in rheumatoid arthritis, targeting initiation in 2027 and a 12‑week data readout in 2028.
Chemomab Therapeutics Ltd. is reported to have a significant shareholder, Touchstone Global Investments Pty Ltd of Australia. Touchstone reports beneficial ownership of 377,814 American Depositary Shares (ADSs), each ADS representing 80 ordinary shares. This holding represents 5.2% of the outstanding ADSs of this class.
Touchstone reports sole voting power and sole dispositive power over all 377,814 ADSs, with no shared voting or dispositive power. The position is reported on a Schedule 13G, indicating a passive ownership filing status as of the reported date.
Chemomab Therapeutics Ltd. investor Erik Otto filed an amended Schedule 13G reporting his beneficial ownership of the company’s American Depository Shares (ADSs). He reports beneficial ownership of 90,000 ADSs, each ADS representing twenty ordinary shares with no par value.
Based on 7,200,377 ADSs outstanding as of May 14, 2026, this position represents 1.2% of the class. Otto reports sole voting power and sole dispositive power over all 90,000 ADSs, with no shared voting or dispositive power. The holding is explicitly disclosed as ownership of 5 percent or less of the class.
HBM Healthcare Investments (Cayman) Ltd. reports beneficial ownership of 80,971,680 Ordinary Shares of Chemomab Therapeutics Ltd., representing about 12.5% of the outstanding Ordinary Shares. The position consists of ADSs already held and Ordinary Shares underlying pre-funded warrants exercisable within 60 days.
HBM originally bought 910,000 ADSs and pre-funded warrants for 3,138,583 ADSs in a July 2024 private placement at $1.235 per ADS or warrant, later adjusted by a 1-for-4 reverse stock split that set one ADS equal to eighty Ordinary Shares.
On July 7, 2026 Chemomab agreed to merge with Scipher Medicine Corporation through a U.S. redomiciliation, with the parties expecting the combined company’s common stock to be listed on the Nasdaq Capital Market under the ticker symbol SCIP. Existing holders will receive contingent value rights providing for a $10 million payment on nebokitug’s FDA approval in rheumatoid arthritis and $40 million if its Primary Sclerosing Cholangitis program reaches a Phase III clinical trial. HBM entered a shareholder support agreement to vote all of its current and warrant shares for the merger and has notified the issuer of its intent to increase its warrant ownership cap to 19.99%.
Chemomab Therapeutics signed a definitive merger agreement with Scipher Medicine that will combine their businesses under a new U.S. parent company expected to trade on Nasdaq as “SCIP.” The structure includes a redomiciling of Chemomab to the U.S. and Scipher becoming a wholly owned subsidiary.
Pre‑merger Scipher securityholders are expected to own about 68% of the combined company and Chemomab holders about 32% on a fully diluted basis, before a concurrent private placement. A syndicate of existing Scipher investors has committed at least $30 million in a PIPE financing at a $150 million pre‑money valuation, with 100% warrant coverage. Chemomab holders of ADSs and vested options will also receive contingent value rights tied to milestones for nebokitug.
The combined company plans to focus on advancing nebokitug into an AI‑enabled Phase 2 rheumatoid arthritis trial using Scipher’s PrismRA test, with topline data targeted for the first half of 2028 and an expected cash runway into the second half of 2028. The merger remains subject to shareholder approvals, regulatory clearances, completion of the PIPE, tax rulings in Israel and other customary closing conditions; failure to close in certain scenarios could trigger termination fees of up to $2 million.
Chemomab Therapeutics Ltd. director Gwen A. Melincoff reported an initial option holding in American Depositary Shares. She holds a stock option covering 8,621 underlying ADS with an exercise price of $1.86 per share, granted on June 1, 2026.
The option vests and becomes exercisable in equal monthly installments over a 36‑month period starting on June 1, 2026, and expires on June 1, 2036. This filing is an initial statement of beneficial ownership rather than a market purchase or sale.
Chemomab Therapeutics Ltd. announced several changes to its board and board committees. On June 1, 2026, the board appointed Gwen Melincoff as an independent Class I director and chair of the nominating and governance committee, bringing the board size to five directors.
On May 29, 2026, directors Claude Nicaise and Jill Quigley resigned from the board and the audit committee, with the company stating their resignations were not due to any disagreements over operations, policies, or practices. The board then appointed Neil Cohen and Nissim Darvish to the audit committee, with Cohen as chair, and reorganized the nominating and governance committee to be chaired by Melincoff with Darvish as a member.
Chemomab Therapeutics Ltd. Chief Executive Officer Mor George Adi reported buying American Depositary Shares on the open market. On May 29, 2026, he purchased 4,926 ADS at $2.08 and 4,878 ADS at $2.05, for a total of 9,804 ADS. Additional J-coded entries reflect RSU positions that, according to the footnotes, involved no transaction and are included for informational purposes only, with vesting running in quarterly installments through October 1, 2028 and April 10, 2029.